JPWO2020041501A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020041501A5 JPWO2020041501A5 JP2021509790A JP2021509790A JPWO2020041501A5 JP WO2020041501 A5 JPWO2020041501 A5 JP WO2020041501A5 JP 2021509790 A JP2021509790 A JP 2021509790A JP 2021509790 A JP2021509790 A JP 2021509790A JP WO2020041501 A5 JPWO2020041501 A5 JP WO2020041501A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- amino acid
- seq
- acid sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 claims description 710
- 108091008153 T cell receptors Proteins 0.000 claims description 322
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 322
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 255
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 255
- 102200006531 KRAS G12V Human genes 0.000 claims description 245
- 102000024070 binding proteins Human genes 0.000 claims description 210
- 108091007650 binding proteins Proteins 0.000 claims description 209
- 101700086956 IFNG Proteins 0.000 claims description 186
- 102100016020 IFNG Human genes 0.000 claims description 186
- 239000000203 mixture Substances 0.000 claims description 151
- 239000000427 antigen Substances 0.000 claims description 135
- 108091007172 antigens Proteins 0.000 claims description 134
- 102000038129 antigens Human genes 0.000 claims description 134
- 230000027455 binding Effects 0.000 claims description 102
- 150000001413 amino acids Chemical class 0.000 claims description 95
- 230000014509 gene expression Effects 0.000 claims description 93
- 229920000023 polynucleotide Polymers 0.000 claims description 93
- 239000002157 polynucleotide Substances 0.000 claims description 93
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 102100009279 KRAS Human genes 0.000 claims description 60
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 53
- 210000002865 immune cell Anatomy 0.000 claims description 50
- 241000282414 Homo sapiens Species 0.000 claims description 39
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 claims description 37
- 102000004965 antibodies Human genes 0.000 claims description 36
- 108090001123 antibodies Proteins 0.000 claims description 36
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 31
- 238000006467 substitution reaction Methods 0.000 claims description 29
- 210000000987 Immune System Anatomy 0.000 claims description 28
- 108060007796 SPATA2 Proteins 0.000 claims description 28
- 230000003612 virological Effects 0.000 claims description 27
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 25
- 230000002759 chromosomal Effects 0.000 claims description 23
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims description 22
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 22
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 22
- 210000003071 memory T lymphocyte Anatomy 0.000 claims description 21
- -1 PVR1G (CD112R) Proteins 0.000 claims description 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 12
- 230000004075 alteration Effects 0.000 claims description 12
- 238000003209 gene knockout Methods 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 238000005304 joining Methods 0.000 claims description 11
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 9
- 201000011231 colorectal cancer Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 101700054183 CTLA4 Proteins 0.000 claims description 8
- 102100005310 CTLA4 Human genes 0.000 claims description 8
- 102100016384 HAVCR2 Human genes 0.000 claims description 7
- 101710004393 HAVCR2 Proteins 0.000 claims description 7
- 108060004270 LAG3 Proteins 0.000 claims description 7
- 102100017213 LAG3 Human genes 0.000 claims description 7
- 201000009036 biliary tract cancer Diseases 0.000 claims description 7
- 210000003515 double negative T cell Anatomy 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 6
- 210000000265 Leukocytes Anatomy 0.000 claims description 6
- 102100006047 TIGIT Human genes 0.000 claims description 6
- 101700052319 TIGIT Proteins 0.000 claims description 6
- 230000000735 allogeneic Effects 0.000 claims description 5
- 108091006028 chimera Proteins 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 230000001506 immunosuppresive Effects 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 102100007290 CD274 Human genes 0.000 claims description 3
- 101710012053 CD274 Proteins 0.000 claims description 3
- 102100007370 TRAV8-1 Human genes 0.000 claims description 3
- 101710028822 TRAV8-1 Proteins 0.000 claims description 3
- 102100007367 TRAV8-3 Human genes 0.000 claims description 3
- 101710028826 TRAV8-3 Proteins 0.000 claims description 3
- 102100020561 TRBJ2-3 Human genes 0.000 claims description 3
- 101710038010 TRBJ2-3 Proteins 0.000 claims description 3
- 102100020559 TRBJ2-4 Human genes 0.000 claims description 3
- 101710038013 TRBJ2-4 Proteins 0.000 claims description 3
- 102100004250 TRBV12-4 Human genes 0.000 claims description 3
- 101710039975 TRBV12-4 Proteins 0.000 claims description 3
- 102100008125 TRBV30 Human genes 0.000 claims description 3
- 101710042600 TRBV30 Proteins 0.000 claims description 3
- 230000001809 detectable Effects 0.000 claims description 3
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 3
- 101710043792 BNA2 Proteins 0.000 claims description 2
- 102100009333 BTLA Human genes 0.000 claims description 2
- 101700047069 BTLA Proteins 0.000 claims description 2
- 102100019456 CD276 Human genes 0.000 claims description 2
- 101700015421 CD276 Proteins 0.000 claims description 2
- 102100008614 IDO1 Human genes 0.000 claims description 2
- 101710031171 IDO1 Proteins 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 102100007289 PDCD1LG2 Human genes 0.000 claims description 2
- 101710011976 PDCD1LG2 Proteins 0.000 claims description 2
- 102100008790 TNFRSF14 Human genes 0.000 claims description 2
- 102100014952 VTCN1 Human genes 0.000 claims description 2
- 101700068327 VTCN1 Proteins 0.000 claims description 2
- 230000036725 Vbeta Effects 0.000 claims description 2
- 102100013504 RPL17 Human genes 0.000 claims 2
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 claims 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 claims 1
- 102000004452 Arginases Human genes 0.000 claims 1
- 108020001204 Arginases Proteins 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 102100014174 CD160 Human genes 0.000 claims 1
- 101710039069 CD160 Proteins 0.000 claims 1
- 102100000188 CD244 Human genes 0.000 claims 1
- 101700000388 CD244 Proteins 0.000 claims 1
- 101710042220 GAL5 Proteins 0.000 claims 1
- 101710042195 GAL9 Proteins 0.000 claims 1
- 102100003900 GEM Human genes 0.000 claims 1
- 108060003143 GEM Proteins 0.000 claims 1
- 102100016650 LAIR1 Human genes 0.000 claims 1
- 101700010670 LAIR1 Proteins 0.000 claims 1
- 102100004651 LGALS9 Human genes 0.000 claims 1
- 101710015837 LGALS9 Proteins 0.000 claims 1
- 101710005673 NECTIN2 Proteins 0.000 claims 1
- 102100000486 NECTIN2 Human genes 0.000 claims 1
- 101710036075 VSIR Proteins 0.000 claims 1
- 102100015314 VSIR Human genes 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 101700048563 ido Proteins 0.000 claims 1
- 101710038532 rpl44e Proteins 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 105
- 238000002965 ELISA Methods 0.000 description 89
- 238000004519 manufacturing process Methods 0.000 description 80
- 102000004196 processed proteins & peptides Human genes 0.000 description 79
- 108090000765 processed proteins & peptides Proteins 0.000 description 79
- 150000007523 nucleic acids Chemical group 0.000 description 76
- 229920001184 polypeptide Polymers 0.000 description 73
- 108020004707 nucleic acids Proteins 0.000 description 72
- 235000018102 proteins Nutrition 0.000 description 66
- 101710033922 KRAS Proteins 0.000 description 60
- 206010028980 Neoplasm Diseases 0.000 description 56
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 43
- 210000003719 B-Lymphocytes Anatomy 0.000 description 42
- 230000000694 effects Effects 0.000 description 42
- 201000010099 disease Diseases 0.000 description 37
- 230000028327 secretion Effects 0.000 description 36
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 35
- 229920000033 CRISPR Polymers 0.000 description 32
- 230000002163 immunogen Effects 0.000 description 32
- 230000035772 mutation Effects 0.000 description 31
- 230000001404 mediated Effects 0.000 description 30
- 108010007539 Blocking Antibodies Proteins 0.000 description 29
- 210000004072 Lung Anatomy 0.000 description 29
- 101710035186 BoLA-DQB Proteins 0.000 description 28
- 238000010354 CRISPR gene editing Methods 0.000 description 28
- 102100019764 PDCD1 Human genes 0.000 description 26
- 101700027814 CDR3 Proteins 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 238000003780 insertion Methods 0.000 description 21
- 241000713666 Lentivirus Species 0.000 description 20
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 20
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 20
- 241000700605 Viruses Species 0.000 description 20
- 102000037240 fusion proteins Human genes 0.000 description 20
- 108020001507 fusion proteins Proteins 0.000 description 20
- 238000010212 intracellular staining Methods 0.000 description 20
- 201000005202 lung cancer Diseases 0.000 description 20
- 230000004044 response Effects 0.000 description 20
- 230000001225 therapeutic Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 17
- 102100016662 ERBB2 Human genes 0.000 description 16
- 101700025368 ERBB2 Proteins 0.000 description 16
- 102100020485 HLA-DRB1 Human genes 0.000 description 16
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 16
- 238000010186 staining Methods 0.000 description 16
- 102100016492 CD34 Human genes 0.000 description 15
- 108060001251 CD34 Proteins 0.000 description 15
- 238000004166 bioassay Methods 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 230000004048 modification Effects 0.000 description 15
- 238000006011 modification reaction Methods 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 210000001519 tissues Anatomy 0.000 description 15
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 14
- 210000003171 Lymphocytes, Tumor-Infiltrating Anatomy 0.000 description 14
- 230000000875 corresponding Effects 0.000 description 14
- 108010045030 monoclonal antibodies Proteins 0.000 description 13
- 102000005614 monoclonal antibodies Human genes 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 238000000729 Fisher's exact test Methods 0.000 description 12
- 101700070835 NCOR2 Proteins 0.000 description 12
- 101700080605 NUC1 Proteins 0.000 description 12
- 102100001100 TRAC Human genes 0.000 description 12
- 101700078141 TRAC Proteins 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 101700006494 nucA Proteins 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- 108010042407 Endonucleases Proteins 0.000 description 11
- 102000018358 Immunoglobulins Human genes 0.000 description 11
- 108060003951 Immunoglobulins Proteins 0.000 description 11
- 230000002068 genetic Effects 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 229920005681 CRISPR RNA Polymers 0.000 description 10
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 10
- 108020004999 Messenger RNA Proteins 0.000 description 10
- 101710003986 ZNF292 Proteins 0.000 description 10
- 102100018612 ZNF292 Human genes 0.000 description 10
- 230000035492 administration Effects 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229920002106 messenger RNA Polymers 0.000 description 10
- 238000011002 quantification Methods 0.000 description 10
- 230000003248 secreting Effects 0.000 description 10
- 102100002977 CDR1 Human genes 0.000 description 9
- 101700073818 CDR1 Proteins 0.000 description 9
- 108009000261 Non-homologous end joining Proteins 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 229920001405 Coding region Polymers 0.000 description 8
- 101700038481 PWP2 Proteins 0.000 description 8
- 102100009676 PWP2 Human genes 0.000 description 8
- 230000002998 immunogenetic Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 101700027746 AGO2 Proteins 0.000 description 7
- 102100010884 AGO2 Human genes 0.000 description 7
- 102100010489 GUCY1A1 Human genes 0.000 description 7
- 101710036435 GUCY1A1 Proteins 0.000 description 7
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 7
- 102100004070 SREK1 Human genes 0.000 description 7
- 101700065992 SREK1 Proteins 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229960000060 monoclonal antibodies Drugs 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102100005826 CD19 Human genes 0.000 description 6
- 101700087100 CD19 Proteins 0.000 description 6
- 102100019461 CD28 Human genes 0.000 description 6
- 101700033362 CD28 Proteins 0.000 description 6
- 102000004533 Endonucleases Human genes 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 102100008254 SELL Human genes 0.000 description 6
- 101710038663 SELL Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000000240 adjuvant Effects 0.000 description 6
- 230000001413 cellular Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000001976 improved Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000003211 malignant Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 229960005486 vaccines Drugs 0.000 description 6
- 206010003816 Autoimmune disease Diseases 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- 210000004698 Lymphocytes Anatomy 0.000 description 5
- 240000003670 Sesamum indicum Species 0.000 description 5
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000259 anti-tumor Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000003463 hyperproliferative Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000036961 partial Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000000865 phosphorylative Effects 0.000 description 5
- 230000001177 retroviral Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 4
- 102100008151 CCR7 Human genes 0.000 description 4
- 108010082319 CRISPR-Associated Protein 9 Proteins 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920000665 Exon Polymers 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 229920002459 Intron Polymers 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 101800001171 Leader peptide Proteins 0.000 description 4
- 101700036258 MECOM Proteins 0.000 description 4
- 102100000165 MS4A1 Human genes 0.000 description 4
- 101710010909 MS4A1 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101710037934 QRSL1 Proteins 0.000 description 4
- 101710034060 RUNX1T1 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001086 cytosolic Effects 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000004077 genetic alteration Effects 0.000 description 4
- 231100000118 genetic alteration Toxicity 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 230000001613 neoplastic Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 230000001131 transforming Effects 0.000 description 4
- 210000004881 tumor cells Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 241000432074 Adeno-associated virus Species 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- 229960001230 Asparagine Drugs 0.000 description 3
- 229960005261 Aspartic Acid Drugs 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 238000010453 CRISPR/Cas method Methods 0.000 description 3
- 102100014838 FCGRT Human genes 0.000 description 3
- 101710003435 FCGRT Proteins 0.000 description 3
- 241000713800 Feline immunodeficiency virus Species 0.000 description 3
- 241001663880 Gammaretrovirus Species 0.000 description 3
- 229960002743 Glutamine Drugs 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 102100006815 IL2RA Human genes 0.000 description 3
- 101700082799 IL2RA Proteins 0.000 description 3
- 102100014194 IL7R Human genes 0.000 description 3
- 101710025228 IL7R Proteins 0.000 description 3
- 101700015336 ISG20 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- 206010025650 Malignant melanoma Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010019706 Nivolumab Proteins 0.000 description 3
- 239000012270 PD-1 inhibitor Substances 0.000 description 3
- 229940121655 PD-1 inhibitors Drugs 0.000 description 3
- 241000712907 Retroviridae Species 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003394 haemopoietic Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 description 3
- 200000000018 inflammatory disease Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001124 posttranscriptional Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000011778 trisodium citrate Substances 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 102100008450 AFP Human genes 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 102100006400 CSF2 Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010035563 Chloramphenicol O-Acetyltransferase Proteins 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 229940104302 Cytosine Drugs 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 241000214054 Equine rhinitis A virus Species 0.000 description 2
- 101700051117 FUT1 Proteins 0.000 description 2
- 210000004700 Fetal Blood Anatomy 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 208000000666 Fowlpox Diseases 0.000 description 2
- 241000535040 Gill-associated virus genotype 2 Species 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241001587547 Grapevine virus G Species 0.000 description 2
- 229920002391 Guide RNA Polymers 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 210000001616 Monocytes Anatomy 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 102100009139 NGF Human genes 0.000 description 2
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 2
- 229940053128 Nerve Growth Factor Drugs 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 241000714209 Norwalk virus Species 0.000 description 2
- 229940098444 Opdivo Drugs 0.000 description 2
- 229940043515 Other immunoglobulins in ATC Drugs 0.000 description 2
- 241000713747 Ovine lentivirus Species 0.000 description 2
- 241000164466 Palaemon adspersus Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241000303666 Potato yellowing virus Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000713675 Spumavirus Species 0.000 description 2
- 208000003265 Stomatitis Diseases 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 101710040448 TNFRSF4 Proteins 0.000 description 2
- 102100013135 TNFRSF4 Human genes 0.000 description 2
- 102100009537 TNFRSF9 Human genes 0.000 description 2
- 101710040535 TNFRSF9 Proteins 0.000 description 2
- 108060008443 TPPP Proteins 0.000 description 2
- 102100007344 TRAV8-6 Human genes 0.000 description 2
- 101710028830 TRAV8-6 Proteins 0.000 description 2
- 102100020556 TRBJ2-5 Human genes 0.000 description 2
- 101710038012 TRBJ2-5 Proteins 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001541 Thymus Gland Anatomy 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 241000703392 Tribec virus Species 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000035531 V beta Effects 0.000 description 2
- 208000007089 Vaccinia Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 108010026638 endodeoxyribonuclease FokI Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000003899 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000000415 inactivating Effects 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 201000005505 measles Diseases 0.000 description 2
- 230000001400 myeloablative Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108010026276 pembrolizumab Proteins 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229940115270 poly ICLC Drugs 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 108091007521 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 108060008616 trbD Proteins 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 101710028178 ANPEP Proteins 0.000 description 1
- 210000003165 Abomasum Anatomy 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 210000004381 Amniotic Fluid Anatomy 0.000 description 1
- 229920002287 Amplicon Polymers 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100011514 B2M Human genes 0.000 description 1
- 101710002767 BACOVA_02645 Proteins 0.000 description 1
- 101700004551 BRAF Proteins 0.000 description 1
- 102100004328 BRAF Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 102100003269 CD151 Human genes 0.000 description 1
- 101700010227 CD151 Proteins 0.000 description 1
- 102100000189 CD22 Human genes 0.000 description 1
- 101700020617 CD22 Proteins 0.000 description 1
- 108060001249 CD24 Proteins 0.000 description 1
- 102100000197 CD24 Human genes 0.000 description 1
- 102100016493 CD33 Human genes 0.000 description 1
- 101700017647 CD33 Proteins 0.000 description 1
- 101710040446 CD40 Proteins 0.000 description 1
- 102100013137 CD40 Human genes 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 102100019283 CD52 Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102100019451 CD80 Human genes 0.000 description 1
- 101700080477 CD80 Proteins 0.000 description 1
- 102100019450 CD81 Human genes 0.000 description 1
- 101700062651 CD81 Proteins 0.000 description 1
- 101710043956 CEACAM5 Proteins 0.000 description 1
- 102100011839 CEACAM6 Human genes 0.000 description 1
- 101710043949 CEACAM6 Proteins 0.000 description 1
- 101710043948 CEACAM7 Proteins 0.000 description 1
- 102100001891 CTAG1A Human genes 0.000 description 1
- 101710004449 CTAG1A Proteins 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940121652 CTLA-4 inhibitors Drugs 0.000 description 1
- 229940046731 Calcineurin inhibitors Drugs 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N Carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 1
- 229920002759 Circular DNA Polymers 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 229920001880 Circular RNA Polymers 0.000 description 1
- 229920000062 Coding strand Polymers 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 229950009791 Durvalumab Drugs 0.000 description 1
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 1
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 1
- 102000001301 EGF receptors Human genes 0.000 description 1
- 108060006698 EGF receptors Proteins 0.000 description 1
- 102200049987 ELP5 E14K Human genes 0.000 description 1
- 102100016627 EPHA2 Human genes 0.000 description 1
- 210000002304 ESC Anatomy 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229940082789 Erbitux Drugs 0.000 description 1
- 101700079540 FAS Proteins 0.000 description 1
- 102100016439 FAS Human genes 0.000 description 1
- 101700010580 FLO11 Proteins 0.000 description 1
- 101710030892 FLT1 Proteins 0.000 description 1
- 102100006565 FLT1 Human genes 0.000 description 1
- 102100013182 FLT4 Human genes 0.000 description 1
- 102100008453 FOLH1 Human genes 0.000 description 1
- 101700036477 FOLH1 Proteins 0.000 description 1
- 101700064140 FOXP3 Proteins 0.000 description 1
- 108090001126 FURIN Proteins 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 206010016629 Fibroma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108060003162 GFP Proteins 0.000 description 1
- 102100010042 GHR Human genes 0.000 description 1
- 101700076301 GHR Proteins 0.000 description 1
- 101700039255 GHRHR Proteins 0.000 description 1
- 102100003314 GHRHR Human genes 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- 102100014519 GPNMB Human genes 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 108060005986 Granzymes Proteins 0.000 description 1
- 102000001398 Granzymes Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 101700045135 HBSAG Proteins 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- MAJYPBAJPNUFPV-UHFFFAOYSA-N Histidinyl-Cysteine Chemical compound SCC(C(O)=O)NC(=O)C(N)CC1=CN=CN1 MAJYPBAJPNUFPV-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 102100014734 ICOS Human genes 0.000 description 1
- 101700078331 ICOS Proteins 0.000 description 1
- 102100014263 IGF1R Human genes 0.000 description 1
- 101700025802 IGF1R Proteins 0.000 description 1
- 102100018760 IL3RA Human genes 0.000 description 1
- 101700029869 IL3RA Proteins 0.000 description 1
- 102100008185 IL6R Human genes 0.000 description 1
- 101710022769 IL6R Proteins 0.000 description 1
- 102100008192 IL6ST Human genes 0.000 description 1
- 101710022768 IL6ST Proteins 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 101710036255 ITEVIIIR Proteins 0.000 description 1
- 101710036252 ITEVIIR Proteins 0.000 description 1
- 101710036251 ITEVIR Proteins 0.000 description 1
- 210000001822 Immobilized Cells Anatomy 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- 108010089187 Ipilimumab Proteins 0.000 description 1
- 102100013180 KDR Human genes 0.000 description 1
- 101700033678 KDR Proteins 0.000 description 1
- 101710030888 KDR Proteins 0.000 description 1
- 102100016985 KIT Human genes 0.000 description 1
- 229940022039 Keytruda Drugs 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 102100004400 L1CAM Human genes 0.000 description 1
- 101700039980 L1CAM Proteins 0.000 description 1
- 102100009515 LRP5 Human genes 0.000 description 1
- 101700055993 LRP5 Proteins 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000003738 Lymphoid Progenitor Cells Anatomy 0.000 description 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 102100006037 MUC1 Human genes 0.000 description 1
- 101700052761 MUC1 Proteins 0.000 description 1
- 102100006044 MUC16 Human genes 0.000 description 1
- 101700008449 MUC16 Proteins 0.000 description 1
- 101000529208 MYC Proteins 0.000 description 1
- 101700075357 MYC Proteins 0.000 description 1
- 210000003593 Megakaryocytes Anatomy 0.000 description 1
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O Methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 231100000782 Microtubule inhibitor Toxicity 0.000 description 1
- 229920000460 Mitochondrial DNA Polymers 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 210000000066 Myeloid Cells Anatomy 0.000 description 1
- 210000003643 Myeloid Progenitor Cells Anatomy 0.000 description 1
- 101700001465 NBR1 Proteins 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 210000001178 Neural Stem Cells Anatomy 0.000 description 1
- 102100019816 OSMR Human genes 0.000 description 1
- 101700032890 OSMR Proteins 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 102100006759 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102100002896 PSG2 Human genes 0.000 description 1
- 101700004495 PSG2 Proteins 0.000 description 1
- 101700008337 PSMA Proteins 0.000 description 1
- 108010065129 Patched-1 Receptor Proteins 0.000 description 1
- 102000012850 Patched-1 Receptor Human genes 0.000 description 1
- 229960005492 Pazopanib Hydrochloride Drugs 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N Phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 229950010773 Pidilizumab Drugs 0.000 description 1
- 210000002706 Plastids Anatomy 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 241001672814 Porcine teschovirus 1 Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101700025699 ROBO1 Proteins 0.000 description 1
- 102100017729 ROR1 Human genes 0.000 description 1
- 101710036428 ROR1 Proteins 0.000 description 1
- 101700058902 RORA Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- HELHAJAZNSDZJO-UHFFFAOYSA-L Sodium tartrate Chemical compound [Na+].[Na+].[O-]C(=O)C(O)C(O)C([O-])=O HELHAJAZNSDZJO-UHFFFAOYSA-L 0.000 description 1
- 229960002167 Sodium tartrate Drugs 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 102100003993 TGFBR1 Human genes 0.000 description 1
- 102100006355 TLR7 Human genes 0.000 description 1
- 101700075266 TLR7 Proteins 0.000 description 1
- 102100003096 TNFRSF18 Human genes 0.000 description 1
- 101710038603 TNFRSF18 Proteins 0.000 description 1
- 101710038526 TNFRSF1A Proteins 0.000 description 1
- 102100003095 TNFRSF1A Human genes 0.000 description 1
- 102100003105 TNFRSF1B Human genes 0.000 description 1
- 101710038524 TNFRSF1B Proteins 0.000 description 1
- 101710040533 TNFRSF8 Proteins 0.000 description 1
- 102100009538 TNFRSF8 Human genes 0.000 description 1
- 102100002202 TNFSF12 Human genes 0.000 description 1
- 101710022356 TNFSF12 Proteins 0.000 description 1
- 210000000538 Tail Anatomy 0.000 description 1
- 241001648840 Thosea asigna virus Species 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108091005908 Type I transmembrane proteins Proteins 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 229940055760 Yervoy Drugs 0.000 description 1
- 102100005283 ZAP70 Human genes 0.000 description 1
- 101700083482 ZAP70 Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 201000009200 autoimmune lymphoproliferative syndrome type 4 Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 108091000236 camrelizumab Proteins 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108010054779 cemiplimab Proteins 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002074 deregulated Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108010016436 durvalumab Proteins 0.000 description 1
- 101710019483 ebgA Proteins 0.000 description 1
- 210000003162 effector T lymphocyte Anatomy 0.000 description 1
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108091005938 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 230000000925 erythroid Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101710020181 fz Proteins 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 150000002309 glutamines Chemical class 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000029684 human MYC protein Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 1
- 230000000640 hydroxylating Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 102000027634 intracellular receptors Human genes 0.000 description 1
- 108091007905 intracellular receptors Proteins 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011031 large scale production Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000003735 mesothelin Human genes 0.000 description 1
- 108090000015 mesothelin Proteins 0.000 description 1
- 108091005593 modified peptides Proteins 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000869 mutational Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000000174 oncolytic Effects 0.000 description 1
- 102000025475 oncoproteins Human genes 0.000 description 1
- 108091008124 oncoproteins Proteins 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 description 1
- 101700045617 pdl-1 Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 108010051812 pidilizumab Proteins 0.000 description 1
- 229920003255 poly(phenylsilsesquioxane) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 101710044770 sll1951 Proteins 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002142 suicide Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002992 thymic Effects 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002463 transducing Effects 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007206 transmembrane glycoprotein Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862721439P | 2018-08-22 | 2018-08-22 | |
US62/721,439 | 2018-08-22 | ||
PCT/US2019/047550 WO2020041501A1 (en) | 2018-08-22 | 2019-08-21 | Immunotherapy targeting kras or her2 antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021534752A JP2021534752A (ja) | 2021-12-16 |
JPWO2020041501A5 true JPWO2020041501A5 (US20100268047A1-20101021-C00003.png) | 2022-08-31 |
Family
ID=68000056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021509790A Pending JP2021534752A (ja) | 2018-08-22 | 2019-08-21 | Kras抗原またはher2抗原を標的とする免疫療法 |
Country Status (11)
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
US20240100162A1 (en) * | 2020-12-22 | 2024-03-28 | Amgen Inc. | Mage-b2-specific t-cell receptors |
CN113755495B (zh) * | 2021-09-22 | 2022-09-06 | 陈天睿 | 基因编辑技术在治疗癌症中的应用 |
WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
CN101284873A (zh) * | 1999-06-30 | 2008-10-15 | 科里克萨有限公司 | 用于肺癌治疗和诊断的组合物和方法 |
ES2292994T3 (es) | 2002-03-15 | 2008-03-16 | Cellectis | Meganucleasas hibridas y de cadena sencilla y su utilizacion. |
JP4966006B2 (ja) | 2003-01-28 | 2012-07-04 | セレクティス | カスタムメイドメガヌクレアーゼおよびその使用 |
EP1850860A2 (en) | 2005-01-13 | 2007-11-07 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
EP1945762B1 (en) | 2005-10-18 | 2013-05-01 | Precision Biosciences | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
MX361299B (es) * | 2010-10-05 | 2018-11-30 | Otsuka Pharmaceutical Co Ltd Star | Metodo para activar celulas auxiliares. |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
GB2537000C (en) | 2012-05-25 | 2019-10-09 | Univ California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
DK2921557T3 (en) | 2012-12-12 | 2016-11-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
SG11201504764SA (en) | 2012-12-19 | 2015-07-30 | Amplimmune Inc | Anti-human b7-h4 antibodies and their uses |
GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
AU2014350051A1 (en) | 2013-11-18 | 2016-07-07 | Crispr Therapeutics Ag | CRISPR-Cas system materials and methods |
US9775892B2 (en) * | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
CN106804108B (zh) | 2014-09-12 | 2021-08-10 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
HUE061084T2 (hu) | 2015-02-19 | 2023-05-28 | Compugen Ltd | PVRIG elleni antitestek és alkalmazási eljárások |
BR112017025728A2 (pt) * | 2015-06-16 | 2018-08-07 | Targovax Asa | fragmentos mutantes da proteína ras |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
KR20220163523A (ko) * | 2016-03-31 | 2022-12-09 | 바이오엔테크 유에스 인크. | 신생항원 및 이것의 사용 방법 |
US11723962B2 (en) | 2016-05-04 | 2023-08-15 | Fred Hutchinson Cancer Center | Cell-based neoantigen vaccines and uses thereof |
WO2017193104A1 (en) * | 2016-05-06 | 2017-11-09 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for mart-1 |
-
2019
- 2019-08-21 CA CA3109496A patent/CA3109496A1/en active Pending
- 2019-08-21 WO PCT/US2019/047550 patent/WO2020041501A1/en active Application Filing
- 2019-08-21 US US17/270,400 patent/US20210340201A1/en active Pending
- 2019-08-21 CN CN201980070018.XA patent/CN112912387A/zh active Pending
- 2019-08-21 BR BR112021003031A patent/BR112021003031A8/pt unknown
- 2019-08-21 KR KR1020217007912A patent/KR20210049119A/ko active Search and Examination
- 2019-08-21 EP EP19773210.0A patent/EP3841113A1/en active Pending
- 2019-08-21 MX MX2021001938A patent/MX2021001938A/es unknown
- 2019-08-21 JP JP2021509790A patent/JP2021534752A/ja active Pending
- 2019-08-21 AU AU2019324162A patent/AU2019324162A1/en active Pending
-
2021
- 2021-02-11 IL IL280804A patent/IL280804A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7037577B2 (ja) | 高親和性mage-a1特異的tcr及びその使用 | |
US11458191B2 (en) | Binding proteins specific for RAS neoantigens and uses thereof | |
US20210340201A1 (en) | Immunotherapy targeting kras or her2 antigens | |
US20240165232A1 (en) | Chimeric receptor proteins and uses thereof | |
JP2020535796A (ja) | strepタグ特異的キメラ受容体およびその使用 | |
JP2023105045A (ja) | Braf特異的tcrおよびその使用 | |
JP2023030005A (ja) | 養子細胞治療を改善するための方法 | |
JP2022525099A (ja) | 高アビディティwt1t細胞受容体とその使用 | |
JP2020533289A5 (US20100268047A1-20101021-C00003.png) | ||
US20220267403A1 (en) | Binding proteins specific for 5t4 and uses thereof | |
TW202317602A (zh) | 嵌合多肽 | |
CN113286815B (zh) | 间皮素特异性t细胞受体及其在免疫治疗中的应用 | |
JPWO2020041501A5 (US20100268047A1-20101021-C00003.png) | ||
US20220401537A1 (en) | Chimeric receptor proteins and uses thereof | |
US20220409661A1 (en) | T-cell immunotherapy specific for wt-1 | |
WO2023230014A1 (en) | Binding proteins and engineered cells specific for neoantigens and uses thereof | |
WO2023220718A1 (en) | Binding proteins specific for ras neoantigens and uses thereof |